Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2022-01, Vol.57, p.103435-103435, Article 103435
Main Authors: Krbot Skorić, Magdalena, Rogić, Dunja, Lapić, Ivana, Šegulja, Dragana, Habek, Mario
Format: Article
Language:English
Subjects:
Antibodies, Viral
Azetidines
Benzyl Compounds
BNT162 Vaccine
Correspondence
COVID-19
COVID-19 Vaccines
Humans
Immunity, Humoral
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive - drug therapy
RNA, Viral
SARS-CoV-2
SARS-CoV-2 IgG antibody
Secondary progressive multiple sclerosis
Siponimod
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2021.103435